205 related articles for article (PubMed ID: 17291751)
1. Polypseudorotaxanes of pegylated insulin with cyclodextrins: application to sustained release system.
Higashi T; Hirayama F; Arima H; Uekama K
Bioorg Med Chem Lett; 2007 Apr; 17(7):1871-4. PubMed ID: 17291751
[TBL] [Abstract][Full Text] [Related]
2. Design and evaluation of polypseudorotaxanes of pegylated insulin with cyclodextrins as sustained release system.
Higashi T; Hirayama F; Misumi S; Arima H; Uekama K
Biomaterials; 2008 Oct; 29(28):3866-71. PubMed ID: 18620750
[TBL] [Abstract][Full Text] [Related]
3. Slow-release system of pegylated lysozyme utilizing formation of polypseudorotaxanes with cyclodextrins.
Higashi T; Hirayama F; Yamashita S; Misumi S; Arima H; Uekama K
Int J Pharm; 2009 Jun; 374(1-2):26-32. PubMed ID: 19446755
[TBL] [Abstract][Full Text] [Related]
4. Polypseudorotaxane formation of randomly-pegylated insulin with cyclodextrins: slow release and resistance to enzymatic degradation.
Higashi T; Hirayama F; Misumi S; Motoyama K; Arima H; Uekama K
Chem Pharm Bull (Tokyo); 2009 May; 57(5):541-4. PubMed ID: 19420793
[TBL] [Abstract][Full Text] [Related]
5. Potential use of gamma-cyclodextrin polypseudorotaxane hydrogels as an injectable sustained release system for insulin.
Abu Hashim II; Higashi T; Anno T; Motoyama K; Abd-ElGawad AE; El-Shabouri MH; Borg TM; Arima H
Int J Pharm; 2010 Jun; 392(1-2):83-91. PubMed ID: 20298768
[TBL] [Abstract][Full Text] [Related]
6. Polypseudorotaxanes of pegylated α-cyclodextrin/polyamidoamine dendrimer conjugate with cyclodextrins as a sustained release system for DNA.
Motoyama K; Hayashida K; Higashi T; Arima H
Bioorg Med Chem; 2012 Feb; 20(4):1425-33. PubMed ID: 22277591
[TBL] [Abstract][Full Text] [Related]
7. Potential use of polypseudorotaxanes of pegylated polyamidoamine dendrimer with cyclodextrins as novel sustained release systems for DNA.
Motoyama K; Hayashida K; Arima H
Chem Pharm Bull (Tokyo); 2011; 59(4):476-9. PubMed ID: 21467677
[TBL] [Abstract][Full Text] [Related]
8. Cyclodextrin/poly(ethylene glycol) polypseudorotaxane hydrogels as a promising sustained-release system for lysozyme.
Higashi T; Tajima A; Motoyama K; Arima H
J Pharm Sci; 2012 Aug; 101(8):2891-9. PubMed ID: 22678818
[TBL] [Abstract][Full Text] [Related]
9. Formulation and biological evaluation of glimepiride-cyclodextrin-polymer systems.
Ammar HO; Salama HA; Ghorab M; Mahmoud AA
Int J Pharm; 2006 Feb; 309(1-2):129-38. PubMed ID: 16377107
[TBL] [Abstract][Full Text] [Related]
10. Cyclodextrin-based sustained and controllable release system of insulin utilizing the combination system of self-assembly PEGylation and polypseudorotaxane formation.
Hirotsu T; Higashi T; Motoyama K; Arima H
Carbohydr Polym; 2017 May; 164():42-48. PubMed ID: 28325342
[TBL] [Abstract][Full Text] [Related]
11. Prednisolone-α-cyclodextrin-star PEG polypseudorotaxanes with controlled drug delivery properties.
Bílková E; Sedlák M; Dvořák B; Ventura K; Knotek P; Beneš L
Org Biomol Chem; 2010 Dec; 8(23):5423-30. PubMed ID: 20859603
[TBL] [Abstract][Full Text] [Related]
12. Design and Evaluation of the Highly Concentrated Human IgG Formulation Using Cyclodextrin Polypseudorotaxane Hydrogels.
Higashi T; Tajima A; Ohshita N; Hirotsu T; Abu Hashim II; Motoyama K; Koyama S; Iibuchi R; Mieda S; Handa K; Kimoto T; Arima H
AAPS PharmSciTech; 2015 Dec; 16(6):1290-8. PubMed ID: 25776984
[TBL] [Abstract][Full Text] [Related]
13. A Pseudopolyrotaxane for Glucose-Responsive Insulin Release: The Effect of Binding Ability and Spatial Arrangement of Phenylboronic Acid Group.
Seki T; Abe K; Egawa Y; Miki R; Juni K; Seki T
Mol Pharm; 2016 Nov; 13(11):3807-3815. PubMed ID: 27715064
[TBL] [Abstract][Full Text] [Related]
14. Fabrication of novel coumarin derivative functionalized polypseudorotaxane micelles for drug delivery.
Chang J; Li Y; Wang G; He B; Gu Z
Nanoscale; 2013 Jan; 5(2):813-20. PubMed ID: 23235914
[TBL] [Abstract][Full Text] [Related]
15. Effect of sulfobutyl ether-β-cyclodextrin on bioavailability of insulin glargine and blood glucose level after subcutaneous injection to rats.
Uehata K; Anno T; Hayashida K; Motoyama K; Hirayama F; Ono N; Pipkin JD; Uekama K; Arima H
Int J Pharm; 2011 Oct; 419(1-2):71-6. PubMed ID: 21803140
[TBL] [Abstract][Full Text] [Related]
16. Peak-less hypoglycemic effect of insulin glargine by complexation with maltosyl-β-cyclodextrin.
Uehata K; Anno T; Hayashida K; Higashi T; Motoyama K; Hirayama F; Uekama K; Arima H
Int J Pharm; 2012 Jan; 422(1-2):33-9. PubMed ID: 22020273
[TBL] [Abstract][Full Text] [Related]
17. Glucose-induced release of glycosylpoly(ethylene glycol) insulin bound to a soluble conjugate of concanavalin A.
Liu F; Song SC; Mix D; Baudys M; Kim SW
Bioconjug Chem; 1997; 8(5):664-72. PubMed ID: 9327129
[TBL] [Abstract][Full Text] [Related]
18. Reversible pegylation of insulin facilitates its prolonged action in vivo.
Shechter Y; Mironchik M; Rubinraut S; Tsubery H; Sasson K; Marcus Y; Fridkin M
Eur J Pharm Biopharm; 2008 Sep; 70(1):19-28. PubMed ID: 18495444
[TBL] [Abstract][Full Text] [Related]
19. Sugar-appended polyamidoamine dendrimer conjugates with cyclodextrins as cell-specific non-viral vectors.
Arima H; Motoyama K; Higashi T
Adv Drug Deliv Rev; 2013 Aug; 65(9):1204-14. PubMed ID: 23602906
[TBL] [Abstract][Full Text] [Related]
20. A thermosensitive hydrogel based on quaternized chitosan and poly(ethylene glycol) for nasal drug delivery system.
Wu J; Wei W; Wang LY; Su ZG; Ma GH
Biomaterials; 2007 Apr; 28(13):2220-32. PubMed ID: 17291582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
